Recent studies have suggested a link between targeted-therapy resistance and CMTM6, as CMTM6 is highly expressed in HER2-positive breast cancer and is co-localized with HER2 on the surface of breast cancer cells. This evidence concerns the gene ERBB2 and breast carcinoma.